Changes
/* Global Acne Medications Market */
# [http://www.euromonitor.com Euromonmitor International]
# [http://www.bccresearch.com BCC Research]
# [http://www.ibisworld.com/ IBISWorld Industry Research]
# [http://www.marketresearch.com MarketResearch.com]
# [http://www.frost.com/prod/servlet/frost-home.pag Frost and Sullivan]
[[Image:Acne marketBCC ACNE.jpg|center|thumb|center|632px * 341px|Source:BCC Research,[http://www.marketresearch.com/BCC-Research-v374/Skin-Disease-Treatment-Technologies-Global-7616658]]]
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|<font color="#282828"> Source: Medicines in Development for Skin Diseases 2011, [http://www.phrma.org/sites/default/files/pdf/skindiseases2011.pdf Pharmaceutical Research and Manufacturers of America</font>|-|}, 2011]
===Historic Sales===
* The Acne Treatment Manufacturing OTC industry has maintained strong growth during the past five years. From As per IBIS World estimates from 2007 to 2012, revenue has grown steady, and it is expected to grow at an average annual rate of 2.4% to $2.3 billion.
* Because acne-prone individuals consider treatment products a necessary expense, revenue continued to rise during the recession, though growth did slow as consumers switched to more inexpensive products.
* Increasing prevalence of adult-onset and persistent acne conditions has given rise to new, targeted products and an expanded consumer base, another factor that has aided revenue growth during the period.
* . In 2012, industry revenue is expected to maintain its growth, gaining 2.7% during the year, due to modest improvements in per capita disposable income.
===Industry Forecast===
* From 2012 to 2017, industry revenue is expected to go up an annualized rate of 3.1% to $2.6 7 billion from current level of $2.3 billion. * Improving economic conditions is likely to drive the market, as greater disposable income growth allows consumers to spend on higher-priced over-the-counter (OTC) items.
[[Image:US ACNE2US2018 acne.jpg|center|thumb|center|632px * 341px|Source:IBIS World,[http://www.ibisworld.com/industry/acne-treatment-manufacturing-otc.html]]]
===Major Players in Acne Space===
* As per IBIS World estimates the top three industry players (Johnson & Johnson, Guthy-Renker and Reckitt-Benckiser) hold a combined market share of about 68.1%, in 2012. However, the remainder The rest of the market is characterized by a large number of small and medium-size businesses. J&J commanded over 28.8% of anti-acne preparation sales in 2012. J&J’s closest rival was Guthy Renker , which had a 24.6% share , thanks to its early 2006 acquisition of Boots Healthcare and its time-honored Clearasil brand. followed by Reckitt Benckiser at 14.7%. Share of U.S. Retail Dollar Sales of Anti-Acne Preparations in Mass Channels for 2007 are shown belowMass Channel (Mass channel includes mainstream supermarkets, chain drugstores and mass merchandisers). Various Channels of Distribution:
* Mass channel includes mainstream supermarketsJ&J (Neutrogena, chain drugstores and mass merchandisersClean & Clear, Aveeno, Ambi) commanded over 28. * Prestige includes upscale8% of anti-priced department stores (e.gacne preparation sales in 2012.J&J’s closest rival was Guthy Renker, Bloomingdale's, Nordstrom), beauty chains (SephoraProactiv Solutions), brand-dedicated stores (Aveda, Mwhich had a 24.A6% share followed by Reckitt Benckiser at 14.C.), salons and spas with retail counters, etc7%.* Online Stores* Direct Sales
[[Image:Major PlayersUS Acne Share.jpg |700pxUS Acne Share.jpg|thumb|center|632px * 341px|Source:IBIS World,[http://academicwww.marketresearchibisworld.com/productindustry/displayacne-treatment-manufacturing-otc.asp?productid=1658180&curl=&surl=%2Fsearch%2Fresults.asp%3Fprid%3D925717062%26query%3Dthe%2BU.S.%2Bcosmeceuticals%2Bmarket%26cmdgo%3DGo&prid=925717062 Sourcehtml]]]
===Consumer Target Group & Product Categorization===
